Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

Looking ahead, Insulet provided a strong outlook for 2025, projecting total revenue growth of 16% to 20% in constant currency. The company expects U.S. Omnipod revenue to grow 16% to 20% and ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

Baird last night initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $20 price target The firm believes Beta’s iLet Bionic ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Beta Bionics (NASDAQ:BBNX) stock was inititaed by Baird with a Neutral rating, citing valuation concerns but highlighting the ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

From diet soda to zero-sugar ice cream, artificial sweeteners have been touted as a guilt-free way to indulge our sweet tooth ...

An artificial pancreas combines a glucose monitor with an insulin pump. In this video, Griffin Rodgers, MD, director of diabetes, digestive and kidney disease at the National Institutes of Health, ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...